Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of daratumumab + carfilzomib + dexamethasone versus carfilzomib + dexamethasone in relapsed or refractory multiple myeloma
2016-003554-33Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab, carfilzomib, dexamethasone in multiple myeloma (MM), sponsored by Amgen. Started Jul 2017; status: completed.
02
Drugs
daratumumabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003554-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003554-33.